April 02, 2026 10:22 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead
Moderna

Moderna to apply for emergency authorisation in US and Europe after Covid vaccine shows 100 pc efficacy iagainst severe cases

| @indiablooms | Dec 01, 2020, at 04:43 am

Washington/IBNS: Drug manufacturer Moderna has said after full results of a late stage study showed its Covid-19 vaccine has 94.1% effectiveness and no serious safety concerns, it has decided to apply for US and European emergency authorization on Monday, said a Reuters report.

The company also reported that the vaccine showed consistent efficacy across gender, race, ethnicity and age demographics and proved 100 per cent efficient in protecting against severe cases of the disease that has so far claimed 1.5 million people across the globe, said the report.

Earlier, Pfizer and BioNTech, which had a 95% efficacy rate in trials, received emergency use authorization in the US this year.

According to the report, out of the 196 volunteers who contracted COVID-19 in the trial with more than 30,000 people, 185 were administered a placebo while 11 were given the vaccine.

Moderna said it had 30 severe cases, all of whom were in the placebo group, indicating 100% effectiveness of the vaccine in preventing severe cases.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.